Scarica l'app Stockscreener
88.12
3.87%
3.2587
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$84.86
Aprire:
$84.8
Volume 24 ore:
250.53K
Relative Volume:
0.57
Capitalizzazione di mercato:
$5.88B
Reddito:
-
Utile/perdita netta:
$-224.29M
Rapporto P/E:
-22.59
EPS:
-3.9
Flusso di cassa netto:
$-185.06M
1 W Prestazione:
+5.10%
1M Prestazione:
+11.95%
6M Prestazione:
+36.23%
1 anno Prestazione:
-12.97%
Intervallo 1D:
$82.72
$88.88
Intervallo di 1 settimana:
$82.00
$88.88
Portata 52W:
$55.53
$106.32
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Confronta NUVL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
88.13 | 6.12B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.89 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.42 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.51 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.85 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
334.74 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
Nuvalent Inc. stock trendline breakdown2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Is Nuvalent Inc. showing signs of accumulationJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
What MACD signals say about Nuvalent Inc.Trade Entry Report & Risk Managed Investment Strategies - newser.com
How Nuvalent Inc. stock reacts to oil pricesMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com
Can trapped investors hope for a rebound in Nuvalent Inc.July 2025 WrapUp & Daily Volume Surge Trade Alerts - newser.com
Intraday pattern recognizer results for Nuvalent Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - newser.com
Is Nuvalent Inc. stock a buy before product launchesMarket Trend Review & Precise Buy Zone Tips - newser.com
The Escalator: Eli Lilly, Nuvalent, Lumen Bioscience and more - Medical Marketing and Media
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com South Africa
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating - 富途牛牛
What to expect from Nuvalent Inc. in the next 30 daysJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Will Nuvalent Inc. stock outperform Dow Jones index2025 Key Lessons & AI Driven Price Predictions - newser.com
Is Nuvalent Inc. reversing from oversold territoryQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
Analyzing net buyer seller activity in Nuvalent Inc.Quarterly Risk Review & Free Expert Approved Momentum Trade Ideas - newser.com
Nuvalent, Inc. Stock (NUVL) Opinions on Cancer Therapy Developments and Insider Sale - Quiver Quantitative
Nuvalent chief development officer Noci sells $332k in shares By Investing.com - Investing.com Australia
Nuvalent CFO Balcom sells $2.3m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent chief development officer Noci sells $332k in shares - Investing.com India
Nuvalent CFO Balcom sells $2.3m in NUVL stock - Investing.com
Transcript : Nuvalent, Inc. Presents at UBS Virtual Oncology Day, Oct-01-2025 03 - MarketScreener
Can you recover from losses in Nuvalent Inc.Buy Signal & Weekly Stock Performance Updates - newser.com
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely - 富途牛牛
Price action breakdown for Nuvalent Inc.Market Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Is Nuvalent Inc a good long term investmentEvening Star Patterns & Free Get High Potential Alerts - Early Times
What analysts say about Nuvalent Inc stockSupport Level Holds & Superior Portfolio Investment - earlytimes.in
What drives Nuvalent Inc stock priceRetail Investor Activity & Exceptional Profit Trading - earlytimes.in
Is this a good reentry point in Nuvalent Inc.2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
1.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):